Research Analysts Set Expectations for HURA Q1 Earnings

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Stock analysts at Brookline Capital Markets issued their Q1 2026 EPS estimates for shares of TuHURA Biosciences in a research note issued to investors on Thursday, April 9th. Brookline Capital Markets analyst K. Raja anticipates that the company will earn ($0.10) per share for the quarter. Brookline Capital Markets also issued estimates for TuHURA Biosciences’ Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.38) EPS, FY2027 earnings at ($0.36) EPS and FY2028 earnings at ($0.30) EPS.

A number of other equities research analysts have also commented on the stock. Wall Street Zen raised shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $9.00.

TuHURA Biosciences Stock Performance

NASDAQ:HURA opened at $3.15 on Tuesday. The firm’s fifty day moving average is $1.61 and its 200-day moving average is $1.60. TuHURA Biosciences has a 52 week low of $0.41 and a 52 week high of $4.44. The firm has a market cap of $200.28 million, a P/E ratio of -5.00 and a beta of -0.32.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its holdings in TuHURA Biosciences by 109.0% during the fourth quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock worth $29,000 after buying an additional 19,931 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in TuHURA Biosciences during the fourth quarter worth $30,000. Virtu Financial LLC acquired a new position in TuHURA Biosciences during the third quarter worth $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in TuHURA Biosciences during the second quarter worth $31,000. Finally, Invesco Ltd. acquired a new position in TuHURA Biosciences during the second quarter worth $30,000. 0.62% of the stock is owned by institutional investors.

More TuHURA Biosciences News

Here are the key news stories impacting TuHURA Biosciences this week:

• Positive Sentiment: Brookline Capital Markets sharply raised FY2026 and FY2027 EPS forecasts (FY2026 from ($0.59) to ($0.38); FY2027 from ($0.58) to ($0.36)) and also improved FY2028 to ($0.30) from ($0.44) — a material reduction in projected losses that likely underpins investor buying. Article Title
• Positive Sentiment: Zacks Research raised its FY2026 and FY2027 EPS estimates (FY2026 from ($0.55) to ($0.48); FY2027 from ($0.58) to ($0.51)), reinforcing the view that analyst expectations for future losses are moderating. Article Title
• Neutral Sentiment: Brookline published quarterly forecasts for 2026 showing ongoing negative EPS each quarter (Q1: ($0.10); Q2–Q4: ($0.09)), so while estimates improved year-over-year, the company is still expected to remain unprofitable near-term — a reminder this is a recovery/turnaround story rather than near-term profitability. Article Title

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.